OR WAIT null SECS
The expansion has doubled Cambrex’s footprint to 15,000 ft2, including an added 3500 ft2 of laboratory space.
Cambrex announced on Oct. 12, 2020 that it has completed the expansion of its solid form screening and crystallization process development facility in Edinburgh, Scotland.
According to a company press release, the expansion has doubled Cambrex’s footprint to 15,000 ft2, including an added 3500 ft2 of laboratory space. The expansion also featured the installation of an additional 13 fume cupboards to the laboratory, including three “walk-in” fume cupboards for increased capacity.
The site, which originally housed 50 employees, will now have room for up to 40 more scientists with the potential to expand in the future, the press release said.
“We have seen an increase in demand for services, and specifically for larger-scale crystallization projects, so this expansion increases our efficiency and ability to respond to these requests,” said Tom Loewald, CEO of Cambrex, in the press release. “The work we carry out at the Edinburgh site is one part of Cambrex’s integrated drug substance offering, and the investment increases our flexibility to work on projects at all stages of drug development.”